本帖最后由 老马 于 2013-3-13 13:43 编辑 5 ?9 A- q2 ^9 A3 K( v* D
( {# S3 p& ?5 G- @) S5 t
健择（吉西他滨）+顺铂+阿瓦斯汀
/ R; c9 z/ C# j& R! Q" S Gemzar +Cisplatin + Avastin+ f/ j. K, M0 b! E2 n6 c
http://annonc.oxfordjournals.org/content/21/9/1804.full! A# G& Q2 j! T5 _5 O d/ n& {
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 A+ _. H8 L" C3 ^Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 Q$ C( `! J6 ^9 d; y& N6 [+ XResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. / I; V+ s" `/ v) L p! w: b
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 855)
, \. y" l2 M& Y' Q9 E华为网盘附件：
) Y+ J# r$ U5 L& _% K. P【华为网盘】ava.JPG. e* V, f- I/ U
|
显身卡
